Department of Endocrinology, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, PR China.
Department of Pulmonary and Critical Care Medicine, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, PR China.
Medicine (Baltimore). 2021 Nov 19;100(46):e27869. doi: 10.1097/MD.0000000000027869.
Tuberculosis (TB) is a preventable and treatable disease, but the increased mortality and morbidity associated with TB continues to be a leading cause of death globally. MicroRNA (miRNA)-155 has been recognized as a marker of many lung diseases. However, the effectiveness of this marker for diagnosing TB remains unclear.
A detailed search (updated on February 6, 2021) of literature published in the Wanfang database, EMBASE, PubMed, CNKI, and Cochrane Library was conducted to identify eligible studies suitable for inclusion in the current research. The positive likelihood ratio, negative likelihood ratio, specificity, area under the curve, sensitivity, and diagnostic odds ratio were used to investigate the diagnostic potential of miRNA-155.
A total of 122 studies related to active TB, which completely complied with the inclusion and exclusion criteria of our meta-analysis, were included. The overall results suggested a moderately high diagnostic accuracy and efficacy of miRNA-155, with a specificity of 0.85 (95% confidence interval = 0.77-0.91) and sensitivity of 0.87 (95% confidence interval = 0.76-0.93). The result based on dysregulated status demonstrated that the upregulated group yielded better accuracy and efficacy than the downregulated group. Notably, the accuracy and efficacy of miRNA-155 in pediatric TB were higher than those in adult TB. The results showed that the accuracy and efficacy of miRNA-155 in children were higher than those in adults.
The results of the meta-analysis suggested that miRNA-155 could serve as an effective biomarker for identifying active TB.
结核病(TB)是一种可预防和可治疗的疾病,但与结核病相关的死亡率和发病率增加仍然是全球主要的死亡原因。微小 RNA(miRNA)-155 已被认为是许多肺部疾病的标志物。然而,该标志物对诊断结核病的有效性尚不清楚。
在万方数据库、EMBASE、PubMed、CNKI 和 Cochrane Library 中进行了详细的文献搜索(更新于 2021 年 2 月 6 日),以确定适合纳入本研究的合格研究。使用阳性似然比、阴性似然比、特异性、曲线下面积、敏感性和诊断优势比来评估 miRNA-155 的诊断潜力。
共纳入了 122 项与活动性结核病相关的研究,这些研究完全符合我们荟萃分析的纳入和排除标准。总体结果表明,miRNA-155 的诊断准确性和效能中等偏高,特异性为 0.85(95%置信区间为 0.77-0.91),敏感性为 0.87(95%置信区间为 0.76-0.93)。基于失调状态的结果表明,上调组的准确性和效能优于下调组。值得注意的是,miRNA-155 在儿童结核病中的准确性和效能高于成人结核病。结果表明,miRNA-155 在儿童中的准确性和效能高于成人。
荟萃分析的结果表明,miRNA-155 可作为识别活动性结核病的有效生物标志物。